Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Renewi plc: Application for Block Listing
Renewi plc: Application for Block Listing
Renewi plc: Application for Block Listing
Technip Energies to Address Attendees at the Kepler Cheuvreux Autumn Conference: https://mms.businesswire.com/media/20210325005821/en/867429/5/TECHNIP_ENERGIES_LOGO_HORIZONTAL_RVB.jpg
Technip Energies to Address Attendees at the Kepler Cheuvreux Autumn Conference


Regulatory News:



Technip Energies (PARIS:TE) (ISIN:NL0014559478) announced today that Arnaud Pieton, Chief Executive Officer, will address attendees on Wednesday, September 14, at 12.00 CET at

DGAP-News: Clean Logistics SE: Jürgen Akkermann appointed as CFO of Clean Logistics
DGAP-News: Clean Logistics SE: Jürgen Akkermann appointed as CFO of Clean Logistics
DGAP-News: Clean Logistics SE: Jürgen Akkermann appointed as CFO of Clean Logistics
Allane Mobility Group continues to expand its offering: Complete winter wheels now available as individual product
Allane Mobility Group continues to expand its offering: Complete winter wheels now available as individual product
Allane Mobility Group continues to expand its offering: Complete winter wheels now available as individual product
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Hardman & Co Research on Chesnara Plc (CSN): Robust cash generation in challenging markets
Hardman & Co Research on Chesnara Plc (CSN): Robust cash generation in challenging markets
Hardman & Co Research on Chesnara Plc (CSN): Robust cash generation in challenging markets
SWEF: Transaction in Own Shares
SWEF: Transaction in Own Shares
SWEF: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
Cairn Homes Plc: Transaction in Own Shares
Hardman & Co Research on Neodecortech (NDT.MI): Bright 1H’22, cloudy outlook
Hardman & Co Research on Neodecortech (NDT.MI): Bright 1H’22, cloudy outlook
Hardman & Co Research on Neodecortech (NDT.MI): Bright 1H’22, cloudy outlook
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
FEMSA publishes the provisional interim result of the public tender offer for Valora – participation rate of 84.41%
FEMSA publishes the provisional interim result of the public tender offer for Valora – participation rate of 84.41%
FEMSA publishes the provisional interim result of the public tender offer for Valora – participation rate of 84.41%
DGAP-Adhoc: Major shareholders intend to restructure the board of directors of the SNP SE
DGAP-Adhoc: Major shareholders intend to restructure the board of directors of the SNP SE
DGAP-Adhoc: Major shareholders intend to restructure the board of directors of the SNP SE
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups


Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 (ERBB2)-mutant

Viad Corp Provides Statement on Health of Pursuit President: https://mms.businesswire.com/media/20191205005099/en/583308/5/ViadBlueLogo.jpg
Viad Corp Provides Statement on Health of Pursuit President


Viad Corp (NYSE: VVI), a leading global provider of extraordinary experiences, including hospitality and leisure activities, experiential marketing, and live events, today announced that David

State Street Corporation Announces Date for Release of Third-Quarter 2022 Financial Results and Conference Call Webcast: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24771/405px-State_Street_Corporation_logo.svg.png
State Street Corporation Announces Date for Release of Third-Quarter 2022 Financial Results and Conference Call Webcast


State Street Corporation (NYSE: STT) plans to announce its third-quarter 2022 financial results on Tuesday, October 18, 2022 at approximately 7:30 a.m. ET. The results will be reviewed via webcast

MSG Sports President and CEO Andrew Lustgarten to Step Down, Effective January 1: https://mms.businesswire.com/media/20201106005470/en/836696/5/MSGS_Logo.jpg
MSG Sports President and CEO Andrew Lustgarten to Step Down, Effective January 1


Madison Square Garden Sports Corp. (NYSE: MSGS) (“MSG Sports”) today announced that Andrew Lustgarten, MSG Sports’ President and Chief Executive Officer, is stepping down from his position at the

NexPlayer To Offer Powerful Combination of Video Quality and Protection through Integration with Verimatrix Streamkeeper and Watermarking: https://mms.businesswire.com/media/20200603005395/en/795668/5/VMX+logo+4210606c.jpg
NexPlayer To Offer Powerful Combination of Video Quality and Protection through Integration with Verimatrix Streamkeeper and Watermarking


Regulatory News:



Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Madrid-based NexPlayer has

Special Committee of Startek Updates Stockholders on Status of Preliminary Non-Binding Proposal by CSP: https://mms.businesswire.com/media/20210317005065/en/865538/5/STARTEK_logo.jpg
Special Committee of Startek Updates Stockholders on Status of Preliminary Non-Binding Proposal by CSP


The Special Committee of the Board of Directors of Startek, Inc. (NYSE: SRT) announced today that it has rejected the preliminary, non-binding proposal, dated August 8, 2022, by CSP Management

DGAP-Adhoc:  Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
DGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
DGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1
Ventas to Participate in Investor Meetings at BofA Securities 2022 Global Real Estate Conference: https://mms.businesswire.com/media/20191106005316/en/282462/5/Ventas_logo.jpg
Ventas to Participate in Investor Meetings at BofA Securities 2022 Global Real Estate Conference


Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) announced today that management will participate in investor meetings at the BofA Securities 2022 Global Real Estate Conference (the “BofA

TCS Group Holding PLC announces BOD changes
TCS Group Holding PLC announces BOD changes
TCS Group Holding PLC announces BOD changes
Fuller, Smith & Turner PLC: Holding(s) in Company
Fuller, Smith & Turner PLC: Holding(s) in Company
Fuller, Smith & Turner PLC: Holding(s) in Company
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
Leclanché SA: Leclanché announces changes in its Board of Directors
Leclanché SA: Leclanché announces changes in its Board of Directors
Leclanché SA: Leclanché announces changes in its Board of Directors